Renibus Therapeutics Strengthens IP Position with Additional US Patent
13 avr. 2022 08h00 HE
|
Rénibus Therapeutics Inc.
SOUTHLAKE, Texas, April 13, 2022 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today...